These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 27616574

  • 1. Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
    Wang YQ, Shen AJ, Sun JY, Wang X, Liu HC, Zhang MM, Chen DQ, Xiong B, Shen JK, Geng MY, Zheng M, Ding J.
    Acta Pharmacol Sin; 2016 Dec; 37(12):1587-1596. PubMed ID: 27616574
    [Abstract] [Full Text] [Related]

  • 2. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
    Hashida S, Yamamoto H, Shien K, Ohtsuka T, Suzawa K, Maki Y, Furukawa M, Soh J, Asano H, Tsukuda K, Miyoshi S, Kanazawa S, Toyooka S.
    Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
    [Abstract] [Full Text] [Related]

  • 3. Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
    Yang J, Wu W, Wen J, Ye H, Luo H, Bai P, Tang M, Wang F, Zheng L, Yang S, Li W, Peng A, Yang L, Wan L, Chen L.
    Biomaterials; 2017 Oct; 141():188-198. PubMed ID: 28689115
    [Abstract] [Full Text] [Related]

  • 4. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
    Jang JY, Kim YG, Nam SJ, Keam B, Kim TM, Jeon YK, Kim CW.
    Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
    [Abstract] [Full Text] [Related]

  • 5. Enhanced antitumor activity of erlotinib in combination with the Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
    Ono N, Yamazaki T, Tsukaguchi T, Fujii T, Sakata K, Suda A, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.
    Cancer Sci; 2013 Oct; 104(10):1346-52. PubMed ID: 23863134
    [Abstract] [Full Text] [Related]

  • 6. Arsenic circumvents the gefitinib resistance by binding to P62 and mediating autophagic degradation of EGFR in non-small cell lung cancer.
    Mao J, Ma L, Shen Y, Zhu K, Zhang R, Xi W, Ruan Z, Luo C, Chen Z, Xi X, Chen S.
    Cell Death Dis; 2018 Sep 20; 9(10):963. PubMed ID: 30237564
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
    Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH.
    Cancer Sci; 2014 Oct 20; 105(10):1245-53. PubMed ID: 25117641
    [Abstract] [Full Text] [Related]

  • 8. The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
    Wang J, Wei H, Zhao B, Li M, Lv W, Lv L, Song B, Lv S.
    J Mol Histol; 2014 Dec 20; 45(6):641-52. PubMed ID: 25008024
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
    Yoshimoto M, Hirata M, Kanai Y, Naka S, Nishii R, Kagawa S, Kawai K, Ohmomo Y.
    Biol Pharm Bull; 2014 Dec 20; 37(3):355-60. PubMed ID: 24583857
    [Abstract] [Full Text] [Related]

  • 10. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
    Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY.
    Anticancer Drugs; 2013 Nov 20; 24(10):1039-46. PubMed ID: 23962905
    [Abstract] [Full Text] [Related]

  • 11. Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
    Zhang B, Jiao J, Liu Y, Guo LX, Zhou B, Li GQ, Yao ZJ, Zhou GB.
    PLoS One; 2012 Nov 20; 7(11):e48748. PubMed ID: 23185274
    [Abstract] [Full Text] [Related]

  • 12. PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
    Zhao XM, Pan SY, Huang QL, Lu YN, Wu XH, Chang JH, Liu ZB, Cai XW, Liu Q, Wang JL, Fu XL.
    Oncotarget; 2016 Aug 02; 7(31):49384-49396. PubMed ID: 27283902
    [Abstract] [Full Text] [Related]

  • 13. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y, Zeng Y, Liu T, Du W, Zhu J, Liu Z, Huang JA.
    Respir Res; 2019 Jul 22; 20(1):164. PubMed ID: 31331328
    [Abstract] [Full Text] [Related]

  • 14. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib.
    Rice JW, Veal JM, Barabasz A, Foley B, Fadden P, Scott A, Huang K, Steed P, Hall S.
    Oncol Res; 2009 Jul 22; 18(5-6):229-42. PubMed ID: 20225761
    [Abstract] [Full Text] [Related]

  • 15. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
    Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM.
    PLoS One; 2015 Jul 22; 10(3):e0119832. PubMed ID: 25780909
    [Abstract] [Full Text] [Related]

  • 16. Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
    Galvani E, Giovannetti E, Saccani F, Cavazzoni A, Leon LG, Dekker H, Alfieri R, Carmi C, Mor M, Ardizzoni A, Petronini PG, Peters GJ.
    Neoplasia; 2013 Jan 22; 15(1):61-72. PubMed ID: 23359111
    [Abstract] [Full Text] [Related]

  • 17. Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
    Li X, Fan XX, Jiang ZB, Loo WT, Yao XJ, Leung EL, Chow LW, Liu L.
    Pharmacol Res; 2017 Jan 22; 115():45-55. PubMed ID: 27864022
    [Abstract] [Full Text] [Related]

  • 18. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
    Hong YS, Jang WJ, Chun KS, Jeong CH.
    Oncol Rep; 2014 Jun 22; 31(6):2619-24. PubMed ID: 24789511
    [Abstract] [Full Text] [Related]

  • 19. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
    Jung SK, Lee MH, Lim DY, Lee SY, Jeong CH, Kim JE, Lim TG, Chen H, Bode AM, Lee HJ, Lee KW, Dong Z.
    Mol Carcinog; 2015 Apr 22; 54(4):322-31. PubMed ID: 24974831
    [Abstract] [Full Text] [Related]

  • 20. GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
    Wang L, Liu J, Liu J, Chen X, Chang M, Li J, Zhou J, Bai C, Song Y.
    J Cancer Res Clin Oncol; 2019 Apr 22; 145(4):861-872. PubMed ID: 30661098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.